Scientific

MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis

These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.

Affected Genes

Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].

Ratio Regulation description Class Gene Ontology Gene Accession Minimum Ratio Maximum Ratio

Results: HTML CSV LaTeX

Showing element 1 to 32 of 32 in total

Class: biological process
Gene Ontology: signal transduction

\def\wcA{0.25\textwidth}
\def\wcB{0.25\textwidth}
\def\wcC{0.25\textwidth}
\begin{longtable}{|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Ratio\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Regulation\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
description\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.10867\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Somatoliberin precursor (Growth hormone-releasing factor) (GRF) (Growth hormone-releasing hormone) (GHRH) (Somatocrinin) (Somatorelin) (Sermorelin). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.14915\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Transmembrane emp24 domain-containing protein 1 precursor (Interleukin-1 receptor-like 1 ligand) (Putative T1/ST2 receptor- binding protein). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.1611\vspace{3pt}}&\multirow{6}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Guanylin precursor (Guanylate cyclase activator 2A) (Guanylate cyclase-activating protein 1) (Gap-I) [Contains: HMW-guanylin; Guanylin]. \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.18821\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Cytokine receptor common beta chain precursor (GM-CSF/IL-3/IL-5 receptor common beta-chain) (CD131 antigen) (CDw131). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.19212\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Thyroglobulin precursor. \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.23783\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Centaurin-delta 1 (Cnt-d1) (Arf-GAP, Rho-GAP, ankyrin repeat and pleckstrin homology domain-containing protein 2) (PARX protein). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.24114\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Myosin-15 (Myosin heavy chain 15). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.36911\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Orexigenic neuropeptide QRFP receptor (G-protein coupled receptor 103) (SP9155) (AQ27). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.36997\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Rho GTPase-activating protein 24 (Rho-type GTPase-activating protein 24) (Filamin-A-associated RhoGAP) (FilGAP) (p73RhoGAP) (RhoGAP of 73 kDa) (RAC1- and CDC42-specific GTPase-activating protein of 72 kDa) (RC-GAP72) (Sarcoma antigen NY-SAR-88). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.44004\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Cytokine-like protein 1 precursor (Protein C17). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.49923\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Rap guanine nucleotide exchange factor 1 (Guanine nucleotide-releasing factor 2) (C3G protein) (CRK SH3-binding GNRP). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.5415\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Pleckstrin homology-like domain family B member 2 (Protein LL5-beta). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.61347\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Calmodulin-like protein 5 (Calmodulin-like skin protein). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.61987\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Proteinase-activated receptor 1 precursor (PAR-1) (Thrombin receptor) (Coagulation factor II receptor). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.6384\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Olfactory receptor 6S1. \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.65422\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Uncharacterized protein C9orf117. \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.79094\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Protein FAM65A. \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.80858\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Rhophilin-1 (GTP-Rho-binding protein 1). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.83496\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Protein FAN (Factor associated with N-SMase activation) (Factor associated with neutral sphingomyelinase activation). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.89308\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Ras-related protein Rab-36. \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.93863\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Olfactory receptor 2B2 (Olfactory receptor 6-1) (OR6-1) (Hs6M1-10). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
1.95876\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Ras-related protein Rab-17. \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1.98137\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Nuclear receptor ROR-alpha (Retinoid-related orphan receptor-alpha) (Nuclear receptor RZR-alpha). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2.44552\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Guanine nucleotide-binding protein alpha-14 subunit (G-protein alpha subunit 14). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2.93895\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
TRAF family member-associated NF-kappa-B activator (TRAF-interacting protein) (I-TRAF). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
3.27919\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Calsenilin (Kv channel-interacting protein 3) (KChIP3) (A-type potassium channel modulatory protein 3) (DRE-antagonist modulator) (DREAM). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
3.48558\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
Ephrin type-B receptor 3 precursor (EC 2.7.10.1) (Tyrosine-protein kinase receptor HEK-2) (Tyrosine-protein kinase TYRO6). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
3.52215\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
down\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
Olfactory receptor 4L1 (Olfactory receptor OR14-28). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
3.54799\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta 2 (Transducin beta chain 2) (G protein beta 2 subunit). \vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
3.64872\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
up\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
GTP-binding protein Rhes precursor (Ras homolog enriched in striatum) (Tumor endothelial marker 2). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
4.55371\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
Parathyroid hormone/parathyroid hormone-related peptide receptor precursor (PTH/PTHr receptor) (PTH/PTHrP type I receptor). \vspace{3pt}}\\\cline{1-1}\cline{3-3}
\parbox{\wcA}{\vspace{3pt}\noindent
5.53059\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
rab and DnaJ domain containing \vspace{3pt}}\\\hline
nd{longtable}

Legend:
- The Ratio specifies how much this gene is up/down regulated. When up- or down-regulated must this value respectively be multiplied/divided to obtain the MK5 on concentration based on the MK5 off concentration.

 - The Regulation specifies how this gene is affected when going from the MK5 off cells to the MK5 on cells. 

 - The Class refers to the ontology category, which can be molecular_function, biological_process or cellular_component. 

 - The Gene Ontology terms as linked to the specific gene.

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Accession is the GO accession key. 

 - Minimum Ratio is the lowest expected regulation ratio based on the replicate slides and a 95% symmetric confidence interval.

 - Maximum Ratio is the highest expected regulation ratio based on the replicate slides and a 95% symmetric confidence interval.

- http://analysis.yellowcouch.org/